TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37331369
Drug: Fruquintinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib (5 mg capsule) orally once daily on days 1-21 in 28-day cycles
Study: 37331368
Drug: Etripamil 70
Normalized name: etripamil
DrugBank: Etripamil (DB12605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etripamil 70 mg nasal spray
Study: 37331690
Drug: Intravenous diuretics
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diuretics (HFH event type)
Study: 37331690
Drug: Randomized treatment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized treatment groups
Study: 37331928
Drug: Transpalpebral external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transpalpebral external microcurrent electrical stimulation with the MacuMira device, 4 treatments in the first 2 weeks, and 2 further treatments at weeks 14 and 26.
Study: 37331928
Drug: Sham control
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham control group (no active treatment).
Study: 37332340
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy (SCRT) followed by chemotherapy and immunotherapy
Study: 37332355
Drug: HFB30132A monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFB30132A monoclonal antibody
Study: 37332638
Drug: Dopamine system-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine system-related biomarkers assessed by serial Iodine-123 Ioflupane dopamine transporter (DAT) imaging, genotyping, and levodopa equivalent daily dose (LEDD) recorded at each assessment.
Study: 37332660
Drug: Low-dose ambrisentan
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ambrisentan
Study: 37332660
Drug: High-dose ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High-dose ambrisentan
Study: 37333093
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of age, sex, and three proteins (ANGPT2, CCL5, TIMP1)
Study: 37333204
Drug: L-citrulline 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline 60 mg/kg every 6 hours for 72 hours
Study: 37333529
Drug: Native Opportunities
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native Opportunities to Stop Hypertension (NOSH) intervention, which includes eight weekly tailored telenutrition counseling sessions with a registered dietitian on DASH eating goals and $30 weekly for purchasing DASH-aligned foods.
Study: 37333529
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving printed educational materials about a low-sodium diet and eight weekly $30 grocery orders.
Study: 37333833
Drug: High-definition home-based
Normalized name: ESIKA PRO HD COLOR HIGH DEFINITION COLOR SPF 20 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-definition home-based transcranial alternating current stimulation (HB-tACS) at 40 Hz for 20 minutes, targeting the left angular gyrus, administered over 14 weeks with at least five sessions per week.
Study: 37334213
Drug: 6-month 45-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month 45-mg leuprolide acetate (LA) depot, administered intramuscularly at weeks 0 and 24
Study: 37334213
Drug: 6-month 45-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month 45-mg leuprolide acetate (LA) depot
Study: 37334295
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g of carbohydrates (CHO)
Study: 37334295
Drug: 32 g
Normalized name: PEG-32 Glyceryl Laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 g of carbohydrates (CHO)
Study: 37334295
Drug: Additional 16
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional 16 g of carbohydrates (CHO) if PG was still <3.0 mmol/L at 15 min and <4.0 mmol/L at 45 min post-initial treatment
Study: 37334511
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus multiagent chemotherapy in Ph-negative ALL
Study: 37334511
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus multiagent chemotherapy in Ph-positive ALL
Study: 37334546
Drug: Mineralocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid receptor antagonists (MRA) treatment for at least 6 months
Study: 37334673
Drug: Chemotherapy (selected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (selected by treating physician)
Study: 37335139
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICI) therapy
Study: 37335552
Drug: D/C/F/TAF 675/150/200/10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: D/C/F/TAF 675/150/200/10-mg FDC (test)
Study: 37335552
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of separate agents: darunavir 600 mg, cobicistat 150 mg, emtricitabine/tenofovir alafenamide 200/10-mg FDC (reference)
Study: 37335552
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of separate agents (reference)
Study: 37335611
Drug: Voice-based digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice-based digital health solution to monitor long COVID symptoms using vocal biomarkers
Study: 37335611
Drug: Co-development of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-development of a tailored voice-based digital health solution
Study: 37335817
Drug: Mindfulness-Based Stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Stress Reduction (MBSR) program, consisting of 8 weekly sessions lasting 2.5 hours each and a 6-hour silence retreat during week 6.
Study: 37335963
Drug: mRNA-1273 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (50 µg) booster vaccination and first dose of recombinant zoster vaccine (RZV1) administered concomitantly (Coad group)
Study: 37335963
Drug: mRNA-1273 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (50 µg) booster vaccination and first dose of recombinant zoster vaccine (RZV1) administered sequentially (Seq group)
Study: 37335994
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Acupuncture and Doxylamine-Pyridoxine
Study: 37336007
Drug: Online opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online opioid overdose and naloxone administration education (20-minute video)
Study: 37336055
Drug: Adjunctive perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive perampanel ≤12 mg/day
Study: 37336533
Drug: Mavacamten (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten (starting dose 2.5 mg/day, adjusted during the study)
Study: 37336835
Drug: Preventative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventative therapy consultation
Study: 37336835
Drug: Preventative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventative therapy prescription
Study: 37336877
Drug: mRNA-1010 (50 µg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1010 (50 µg, 100 µg, or 200 µg)
Study: 37336877
Drug: mRNA-1010 (25 µg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1010 (25 µg, 50 µg, or 100 µg)
Study: 37337155
Drug: FOLFIRI-Ram (5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI-Ram (5-FU 2400 mg/m2)
Study: 37337234
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein content (2.0 g of protein/kg/day)
Study: 37337234
Drug: Standard protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protein content (1.3 g of protein/kg/day)
Study: 37337261
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) plus Treatment As Usual (TAU)
Study: 37337269
Drug: Periradicular administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periradicular administration of platelet-rich fibrin (PRF) during surgery
Study: 37337295
Drug: Inhaled xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled xenon administered within 6 hours after the onset of symptoms of aSAH
Study: 37337366
Drug: Cotadutide 600-μg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotadutide 600-μg
Study: 37337747
Drug: Glimepiride 1-2
Normalized name: glimepiride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1-2 mg/day
Study: 37338017
Drug: 0.1-20.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1-20.0 g/day alcohol use (moderate drinkers)
Study: 37338017
Drug: >20.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: >20.0 g/day alcohol use (heavy drinkers)
Study: 37338017
Drug: 0.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 g/day alcohol use (non-drinkers)
Study: 37338130
Drug: Telemedicine for
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine for Reach, Education, Access, Treatment, and Ongoing Support (TREAT-ON) program
Study: 37338150
Drug: Senaparib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senaparib (100 mg QD)
Study: 37338154
Drug: MAS825 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAS825 (10 mg/kg single i.v.) + standard of care (SoC)
Study: 37338355
Drug: Radiomics features
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiomics features in standard-dose CT (model I)
Study: 37338355
Drug: Demographics in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demographics in standard-dose CT
Study: 37338393
Drug: Bemnifosbuvir, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemnifosbuvir, an oral antiviral drug targeting viral RNA polymerase, dosage and duration not specified.
Study: 37338445
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure treatment focusing on sexual assault trauma
Study: 37338445
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure treatment not focusing on sexual assault trauma
Study: 37338608
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K supplementation with oral bisphosphonate, calcium and/or vitamin D
Study: 37338615
Drug: Clonidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (75 μg twice a day)
Study: 37338893
Drug: ApTOLL 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApTOLL 0.2 mg/kg
Study: 37338893
Drug: ApTOLL 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApTOLL 0.05 mg/kg
Study: 37338898
Drug: Technology Assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology Assisted Stepped Collaborative Care (TĀCcare) - 12 weekly sessions of cognitive behavioral therapy via telehealth and/or pharmacotherapy.
Study: 37338906
Drug: Adapted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted therapy (ADT) with nicotine patch (NP) and pharmacotherapy adaptations (varenicline and bupropion+NP)
Study: 37338906
Drug: Adapted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted therapy (ADT) with pharmacotherapy adaptations
Study: 37338929
Drug: Remote monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remote monitoring solutions and digital alerting tools
Study: 37338929
Drug: Recommendations for
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendations for enhancing integration of remote sensing solutions
Study: 37339186
Drug: Ipatasertib 400
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib 400 mg daily plus rucaparib 400 mg twice daily
Study: 37339254
Drug: Trifluridine/tipiracil 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil 25 mg/m2 (days 1-5 of 14-day cycle) and irinotecan 180 mg/m2 (day 1 of the 14-day cycle)
Study: 37339342
Drug: Self-tell notification
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-tell notification (treatment as usual)
Study: 37625088
Drug: DARE-HRT1 IVR1
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DARE-HRT1 IVR1 (E2 80 μg/d with P4 4 mg/d)
Study: 37625088
Drug: DARE-HRT1 IVR2
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DARE-HRT1 IVR2 (E2 160 μg/d with P4 8 mg/d)
Study: 37339441
Drug: d-Amphetamine Transdermal
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine Transdermal System
Study: 37339586
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus vorinostat (Vorinostat 100 mg twice a day for DL1 and 200 mg twice a day for DL2, administered orally from days 1 to 5 and 8 to 12; Pembrolizumab 200 mg IV every 3 weeks)
Study: 37339979
Drug: GVAX vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVAX vaccine with low-dose cyclophosphamide (Arm A)
Study: 37339979
Drug: GVAX vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVAX vaccine with anti-PD-1 antibody nivolumab (Arm B)
Study: 37339979
Drug: GVAX vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVAX vaccine with nivolumab and anti-CD137 agonist antibody urelumab (Arm C)
Study: 37340170
Drug: 4-session intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-session intervention including safety plans with mobile augmentation
Study: 37340170
Drug: 4-session intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-session intervention including safety plans without mobile augmentation
Study: 37340213
Drug: Dog-assisted Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dog-assisted Therapy (DAT)
Study: 37340306
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement + PFMT
Study: 37340369
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy using surgical gloves
Study: 37340397
Drug: Low-dose chemotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chemotherapy (Ara-C) administered at home by parents
Study: 37340397
Drug: Home chemotherapy
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home chemotherapy intervention
Study: 37340439
Drug: MI-oriented adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI-oriented adjunctive treatment (three individual therapy sessions and a self-help manual)
Study: 37340439
Drug: CBT-oriented adjunctive
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-oriented adjunctive treatment (three individual therapy sessions and a self-help manual)
Study: 37340439
Drug: Both MI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both MI and CBT treatments
Study: 37340664
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in anti-CMV antibody in seropositive girls
Study: 37341243
Drug: IDP-126 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-126 gel (clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%)
Study: 37341243
Drug: Dyad gels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyad gels (1 of the 3 dyad gels, phase 2 only)
Study: 37341530
Drug: Nanoparticle-mediated tissue-targeted
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanoparticle-mediated tissue-targeted therapies
Study: 37342080
Drug: RealConsent (internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: RealConsent (internet-based intervention) with 100% dosage
Study: 37342775
Drug: 1-week auto-CPAP
Normalized name: Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week auto-CPAP treatment
Study: 37343084
Drug: Microdialysis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdialysis and ambulatory fraction collector for measuring tissue adrenal steroids
Study: 37343145
Drug: Tanezumab 20
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 20 mg
Study: 37343625
Drug: 10-μg bimatoprost
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10-μg bimatoprost implant
Study: 37344061
Drug: Oral lutein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lutein and zeaxanthin supplementation for three months
Study: 37638838
Drug: Pecan-enriched diet
Normalized name: Pecan
DrugBank: Pecan (DB10555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pecan-enriched diet (68 g of pecans/day)
Study: 37344265
Drug: Ad26.COV2.S booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.COV2.S booster dose (5 × 10^10 viral particles)
Study: 37344474
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg IV every 3 weeks) plus weekly paclitaxel (80 mg/m2)
Study: 37344474
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg IV every 3 weeks) plus flat-dose capecitabine
Study: 37344582
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ophthalmologists and DLA-RB
Study: 37344751
Drug: Inhaled PUR1900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled PUR1900 (itraconazole) at doses up to 40 mg per day
Study: 37344751
Drug: Midazolam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (5 mg) co-administered with inhaled PUR1900
Study: 37344789
Drug: Open Discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open Discontinuation (OD)
Study: 37344789
Drug: Hidden Discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hidden Discontinuation (HD)
Study: 37344801
Drug: Fluid administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administration of 250 ml of crystalloid fluid
Study: 37344895
Drug: Ropeginterferon alfa-2b
Normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ropeginterferon alfa-2b at a dosing regimen of 250-350-500 μg
Study: 37344895
Drug: Approved dosing
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approved dosing schema of ropeginterferon alfa-2b (starting dose of 100 µg)
Study: 37344997
Drug: Oxycodone 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.05 mg/kg
Study: 37345196
Drug: Ruxolitinib (JAK1/JAK2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (JAK1/JAK2 inhibitor)
Study: 37345256
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of autologous culture-expanded adipose-derived mesenchymal stem cells (ADMSCs)
Study: 37345876
Drug: Bulevirtide 2
Normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Bulevirtide 2 mg per day for 144 weeks
Study: 37345876
Drug: Bulevirtide 10
Normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Bulevirtide 10 mg per day for 144 weeks
Study: 37345876
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for 48 weeks followed by bulevirtide 10 mg per day for 96 weeks)
Study: 37345996
Drug: Combination intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination intervention (acute HIV testing, contract partner notification (cPN), and social contact referral)
Study: 37346899
Drug: Gothenburg Treatment
Normalized name: Hb Gothenburg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gothenburg Treatment for Gaming Disorder (GOT-TO-GO) manual; a 15-week cognitive behavioral therapy treatment for GD
Study: 37347015
Drug: Osteoconductive scaffold
Normalized name: Viable and metabolically active allogeneic human NIKS keratinocytes and human dermal fibroblasts cellularized layered scaffold
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoconductive scaffold augmentation at the femoral tunnel aperture
Study: 37347015
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with femoral fixation using cortical suspension fixation and secondary press-fit fixation
Study: 37347370
Drug: Inhaled IFN-α2b
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled IFN-α2b 2.5 MIU twice daily for 10 days (n = 6)
Study: 37347370
Drug: Inhaled IFN-α2b
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled IFN-α2b 5.0 MIU twice daily for 10 days (n = 6)
Study: 37347370
Drug: Inhaled IFN-α2b
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled IFN-α2b (both doses)
Study: 37347553
Drug: Antibody responses
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody responses
Study: 37347913
Drug: In-home telehealth
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-home telehealth cognitive behavioral treatment